TOLERA trial in RA RTX/ABA sequence versus RTX alone 10pts each group Primary outcome was ambitious: ACPA seroconversio
Tweet Content
TOLERA trial in RA
RTX/ABA sequence versus RTX alone
10pts each group
Primary outcome was ambitious: ACPA seroconversion
No difference between ttmts (and also no seroconversion)
No diff in disease activity
No diff in ACPA change wt wk52
@RheumNow OP0069 #EULAR2024 https://t.co/0EM7XRzfNo
Show on Archive Page
On
Display in Search Results
On
PDQ
Off